Navigation Links
Isis Initiates Clinical Trial of CRP Drug
Date:8/13/2008

Reduction of CRP with ISIS 353512 could provide therapeutic benefit in

cardiovascular, renal and inflammatory diseases

CARLSBAD, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today it has initiated a Phase 1 study of ISIS 353512, an antisense drug that inhibits the production of C-reactive protein (CRP). CRP levels are frequently elevated in patients with a variety of diseases including cardiovascular disease, Crohn's disease, rheumatoid arthritis and end-stage renal disease. The Phase 1 study of ISIS 353512 is a blinded, randomized, placebo-controlled, dose-escalation study designed to assess the safety and pharmacokinetic profile of ISIS 353512 as well as to assess the initial effects of the drug on baseline CRP levels in healthy volunteers. In addition, Isis is designing a broad Phase 2 program to investigate multiple indications for ISIS 353512.

"We believe that CRP plays an important causal role not only in cardiovascular disease but also in renal and inflammatory diseases. Based on our preclinical data, and the safety and pharmacological data we will obtain from this study, we plan to create a Phase 2 development plan that evaluates several of the most scientifically and commercially attractive indications for ISIS 353512," said Stanley Crooke, Chairman and Chief Executive Officer of Isis. "CRP is an excellent example of the power of our technology which enables us to efficiently develop drugs to any target and to select targets that provide the most significant therapeutic benefit in disease areas where new treatment options are desperately needed."

ISIS 353512 Targets CRP

ISIS 353512 is an antisense drug that targets CRP. For many years, CRP has been used as a clinical biomarker of diseases with an inflammatory component, such as cardiovascular disease, Crohn's disease, rheumatoid arthritis and end-stage renal disease. Elevated levels of CRP have been linked to coronary artery disease and a growing body of evidence from clinical trials implicates CRP in cardiovascular disease progression. Although CRP's active participation in these diseases remains to be determined, several lines of evidence support a causal role of CRP in disease, suggesting that it may be therapeutically beneficial to decrease CRP levels in patients who are at risk for coronary events. In addition, elevated CRP levels have been associated with a worsening of overall outcome in conditions such as end-stage renal disease, suggesting that lowering CRP in these patients would be beneficial. In preclinical studies, ISIS 353512 produced dramatic suppression of liver and serum CRP levels.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis' discovery and development of drugs for cardiovascular diseases, and the potential of the antisense drug ISIS 353512 to treat cardiovascular, renal and inflammatory diseases. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward- looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, and its quarterly report on Form 10-Q for the quarter ended June 30, 2008, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
2. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
3. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
4. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
7. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
8. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
9. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
10. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
11. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
(Date:5/26/2016)... , May 26, 2016   Change ... and analytics, network solutions and technology-enabled services ... it entered into a strategic channel partnership ... outpatient software solutions and revenue cycle management ... hospitals and rehabilitation clinics to optimize revenue, ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
Breaking Medicine Technology:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... provider of comprehensive treatment for eating disorders, is opening a brand new child ... provide individuals ages 8-17 and their families with even more specialized eating disorder ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), Brian ... Regeneration. The conference was held during May 5-6, 2016 in Chicago, IL, USA. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer of the ... more than humbled by customer demand over the Mother’s Day Weekend promotion. So much ... that Bunion Bootie has completely replenished its inventory levels, it hopes to continue its ...
(Date:5/26/2016)... ... 26, 2016 , ... The introduction of our professional athletes coincides with the ... , “We are proud to introduce Meghan Klingenberg, defender and World Champion ... Quick, wide receiver for Los Angeles who was a second round selection in the ...
(Date:5/26/2016)... ... May 26, 2016 , ... May 2016 – Lips ... central to popular cosmetic improvement efforts. Record numbers of clients now ask about lip ... or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , The ...
Breaking Medicine News(10 mins):